Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Authors' conclusion
Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72.
Study context
- Population
- Adults with obesity but without T2Drandomized 1:1
- Participants
- 751 adults
- Comparison
- Tirzepatide vs semaglutide, maximum tolerated dose, SC once weekly for 72 weeks
- Primary endpoint
- Percent change in weight from baseline
- Follow-up
- Week 72
Methodological detailsphase 3b, open-label
- Phase 3b
- Open-label
Primary result
As reported in the abstract
Percent change in weight
Tirzepatide
−20.2
least-squares mean · 95% CI −21.4–-19.1 · %
Semaglutide
−13.7
least-squares mean · 95% CI −14.9–-12.6 · %
P < 0.001
Secondary outcomes
Least-squares mean, cm
| Outcome | Tirzepatide | Semaglutide | P value |
|---|---|---|---|
| Change in waist circumference · week 72 | −18.4 (95% CI −19.6–-17.2) | −13.0 (95% CI −14.3–-11.7) | P < 0.001 |
Weight reductions of at least 10%, 15%, 20% and 25% · week 72
- Tirzepatide participants more likely than semaglutide participants to have weight reductions of at least 10%, 15%, 20% and 25%
Safety
Adverse events
- Most common AEs in both groups were gastrointestinal, mostly mild to moderate and primarily during dose escalation
Original publication
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. Published 11 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →